Long-term, open-label safety and tolerability study of once-daily extended-release oxcarbazepine (oxtellar XR™) as adjunctive therapy in patients with refractory partialonset seizures

Authors
Category Primary study
JournalEpilepsy Currents
Year 2013
This article has no abstract
Epistemonikos ID: a0d4089df342e580792b130f49d235ce3bd7a428
First added on: Feb 05, 2025